Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
about
Integration of multiparametric MRI into active surveillance of prostate cancer.Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy.Defining the Costs of Reusable Flexible Ureteroscope Reprocessing Using Time-Driven Activity-Based Costing (TDABC).Erectile Function after Stereotactic Body Radiotherapy for Localized Prostate Cancer.Therapeutic Ultrasound and Prostate Cancer.Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated healthcare system.When should active surveillance for prostate cancer stop if no progression is detected?Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.[Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study].The Cost of Penicillin Allergy Evaluation.Trends in active surveillance for very low-risk prostate cancer: do guidelines influence modern practice?Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.Determining the Cost-Savings Threshold and Alignment Accuracy of Patient-Specific Instrumentation in Total Ankle Replacements.
P2860
Q30249514-C6F037B5-B879-4B59-BC28-14F92D049A27Q30400574-461CB340-0A1F-43AD-A08A-9FB6DF354F8FQ38613873-AA6EA005-F643-4008-9092-876044AFDD3DQ38677828-7A049D7F-C147-4A7A-8E92-19FD625BDCB5Q38745164-BC062374-9655-44A7-A948-2377A8814821Q38769344-0144C9D3-75D7-477B-A120-202447A29911Q38832126-0C1DD09A-E811-4051-965A-1FB7B373CBFDQ39736576-FEC06FD8-C7A8-4E1A-AF8E-107D1A6EA5FBQ40485174-FC9897EE-A9B8-45F9-953D-FC89F084F802Q41993304-69B259EE-51EA-48B8-8EE5-D6CC6599E41DQ42373315-668DF980-2D3F-4E50-BB26-59CE476D8A6AQ47185878-43EB7AF4-0C32-4E37-A2D2-DD15C84637D9Q47324732-C1830758-8513-41E8-BE47-E10594907448Q51158322-71EC900B-3212-45C8-937A-BD01412337B2
P2860
Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@en
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@nl
type
label
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@en
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@nl
prefLabel
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@en
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Utilizing time-driven activity ...... zed, low-risk prostate cancer.
@en
P2093
Aaron A Laviana
Alan L Kaplan
Andrew K Moriarity
Annette M Ilg
Chandan R Kundavaram
Chris R King
Christopher S Saigal
Daniel J A Margolis
Darlene Veruttipong
Douglas R Niedzwiecki
P2860
P304
P356
10.1002/CNCR.29743
P407
P50
P577
2015-11-02T00:00:00Z